Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) EPS (Weighted Average and Diluted) (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.46 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 62.6% year-over-year to -$0.46, compared with a TTM value of -$0.79 through Dec 2025, up 78.47%, and an annual FY2025 reading of -$0.79, up 78.53% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.46 for Q4 2025 at SAB Biotherapeutics, down from $1.32 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.32 in Q3 2025 and bottomed at -$3.85 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.7, with a median of -$0.5 recorded in 2025.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 7400.0% in 2023, then skyrocketed 218.92% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.41 in 2021, then tumbled by 341.27% to -$1.81 in 2022, then crashed by 112.8% to -$3.85 in 2023, then soared by 68.05% to -$1.23 in 2024, then soared by 62.6% to -$0.46 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for SABS at -$0.46 in Q4 2025, $1.32 in Q3 2025, and -$1.09 in Q2 2025.